UroGen To Host Investor Day on September 24, 2019 Spotlighting Clinical Development Updates and UGN-101 Launch Readiness

Sept. 10, 2019 12:00 UTC



NEW YORK--(BUSINESS WIRE)-- UroGen Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced that it will host an Investor Day on September 24, 2019 in New York where the Company will share updates on its clinical programs and launch readiness plans for UGN-101 (mitomycin gel) for instillation, its lead product candidate for the treatment of patients with low-grade upper tract urothelial cancer (LG UTUC). The program will also highlight the Company’s vision and strategy and include a panel discussion with key opinion leaders on the treatment of LG UTUC and low-grade non-muscle invasive bladder cancer.

The live audio webcast and accompanying slide presentation will begin at 10:00AM Eastern Time. The live audio webcast can be accessed through the Events and Presentations section under the Investors tab of UroGen’s website at www.urogen.com. Following the live audio webcast, a replay will be available on UroGen’s website for approximately 30 days.

Management will also present at two investor conferences in September:

H.C. Wainwright 21st Annual Global Investment Conference

  • Tuesday, September 10th
  • 10:50AM Eastern Time
  • New York, NY

Ladenburg Thalmann Healthcare Conference

  • Tuesday, September 24th
  • 3:00PM Eastern Time
  • New York, NY

A live audio webcast of each event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of each webcast will be available on the website for approximately two weeks.

About UroGen Pharma Ltd.

UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to potentially ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Los Angeles, CA and Israel.

Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the potential of UGN-101 for LG UTUC; the potential approval of UGN-101 and the timing thereof; the timing for completion of pre-commercial activities and infrastructure build-out in anticipation of a potential commercial launch of UGN-101; the potential of UroGen’s proprietary RTGel™ technology platform to improve therapeutic profiles of existing drugs; the opportunity and potential of UGN-102 for LG NMIBC. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the timing and success of clinical trials, including the OLYMPUS Phase 3 trial and the OPTIMA II Phase 2b trial and potential safety and other complications thereof; the ability to obtain regulatory approval within the timeframe expected, or at all; the ability to maintain regulatory approval; complications associated with achieving commercial readiness for the launch of a new product; the labeling for any approved product; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; and UroGen’s ability to attract or retain key management, members of the board of directors and personnel. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Form 10-Q filed with the SEC on August 9, 2019 and other filings that UroGen makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.


Kate Bechtold
Senior Director, Investor Relations


Source: UroGen Pharma Ltd.

Back to news